A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE₂-mediated immunosuppression and inhibits breast cancer metastasis

Xinrong Ma,1 Dawn Holt,1 Namita Kundu,1,2 Jocelyn Reader,1 Olga Goloubeva,1 Yukinori Take3 and Amy M. Fulton1,2,4,*

1University of Maryland Greenebaum Cancer Center; Baltimore, MD USA; 2Department of Pathology; University of Maryland; Baltimore, MD USA; 3RaQualia Pharma Inc.; Aichi, Japan; 4Baltimore Veterans Administration Medical Center; Baltimore, MD USA

Keywords: EP4, immunosuppression, metastasis, NK cells, prostaglandin E, prostaglandin E receptor

Abbreviations: cAMP, cyclic adenosine monophosphate; COX-2, cyclooxygenase 2; EGR-1, early growth response gene-1; EP4, prostaglandin E receptor 4; FBS, fetal bovine serum; IBMX, 1-methyl-3-isobutylxanthine; IDO, indoleamine-pyrole 2,3-dioxygenase; IFNγ, interferon γ; IL2, interleukin 2; MIP1α, macrophage inflammatory protein 1α; NK, natural killer; N-NK, NK from normal mice; NSCLC, non-small cell lung carcinoma; PGE₂, prostaglandin E₂; PI3K, phosphoinositide-3-kinase; SDF1α, stromal cell derived factor 1α; T-NK, NK from tumor-bearing mice

Cyclooxygenase-2 is frequently upregulated in epithelial tumors and contributes to poor outcomes in multiple malignancies. The COX-2 product prostaglandin E₂ (PGE₂) promotes tumor growth and metastasis by acting on a family of four G protein-coupled receptors (EP1–4). Using a novel small molecule EP4 antagonist (RQ-15986) and a syngeneic murine model of metastatic breast cancer, we determined the effect of EP4 blockade on innate immunity and tumor biology. Natural killer (NK)-cell functions are markedly depressed in mice bearing murine mammary tumor 66.1 or 410.4 cells owing to the actions of PGE₂ on NK cell EP4 receptors. The EP4 agonist PGE₂-OH inhibits NK functions in vitro, and this negative regulation is blocked by RQ-15986. Likewise, the treatment of tumor-bearing mice with RQ-15986 completely protected NK cells from the immunosuppressive effects of the tumor microenvironment in vivo. RQ-15986 also has direct effects on EP4 expressed by tumor cells, inhibiting the PGE₂-mediated activation of adenylate cyclase and blocking PGE₂-induced tumor cell migration. The pretreatment of tumor cells with a non-cytotoxic concentration of RQ-15986 inhibited lung colonization, a beneficial effect that was lost in mice depleted of NK cells. The oral administration of RQ-15986 inhibited the growth of tumor cells implanted into mammary glands and their spontaneous metastatic colonization to the lungs, resulting in improved survival. Our findings reveal that EP4 antagonism prevents tumor-mediated NK-cell immunosuppression and demonstrates the anti-metastatic activity of a novel EP4 antagonist. These observations support the investigation of EP4 antagonists in clinical trials.

Introduction

The cyclooxygenase-2 (COX-2) product prostaglandin E₂ (PGE₂) mediates tumor-associated immunosuppression. Natural killer (NK) cells, which play a critical role in the control of metastases, are inhibited by PGE₂ acting on the cognate receptors EP2 and EP4.1,2 Previous studies from us and other laboratories support a key role for EP4 in promoting breast cancer metastasis,3–9 but until now there have been few effective EP4 antagonists available for preclinical and clinical investigations. Here, we describe a novel orally active EP4 antagonist, RQ-00015986 (hereafter abbreviated RQ-15986, CJ-042794).10 In clinical trials, the RQ-15986-related compound RQ-07 has been shown to be safe and efficient against osteoarthritis-associated pain (unpublished observations) and is the only known EP4 antagonist available for clinical evaluation. The effects of RQ-15986 on innate immunity have not yet been investigated nor has its ability to inhibit tumor metastasis been determined. We now report that RQ-15986 restores the profound suppression of NK-cell functions that characterizes progressive tumor growth, an effect that is accompanied by marked antitumor and antimetastasis activity. These studies identify a potential new approach to prevent tumor-associated NK-cell suppression.

*Correspondence to: Amy M. Fulton; Email: afulton@umaryland.edu
Submitted: 09/14/12; Revised: 10/23/12; Accepted: 10/23/12
http://dx.doi.org/10.4161/onci.22647.
Citation: Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE₂-mediated immunosuppression and inhibits breast cancer metastasis. OncoImmunology 2013; 2:e22647
Results

A novel non-cytotoxic inhibitor of EP4. RaQualia Pharma has developed several high-affinity and highly selective EP4 antagonists. RQ-15986 (Fig. 1A) potently inhibits PGE₂-mediated elevations in cAMP activity in HEK293 cells expressing murine EP4 (pA₂ value of 8.7). In malignant cells derived from the mammary gland, EP4 is similarly coupled to adenylate cyclase activation. We examined the ability of RQ-15986 to inhibit this response in malignant cells exposed to PGE₂, or the EP4-specific agonist PGE₁-OH (Fig. 1B). Stimulation of murine 66.1 mammary tumor cells with 5 μM PGE₂ or PGE₁-OH for 15 min resulted in a 2.1- or 2-fold elevation in intracellular cAMP, respectively. These responses were significantly inhibited by the EP4 antagonists AH23848 or RQ-15986 in a dose dependent manner. The ability of RQ-15986 to inhibit PGE₂-mediated adenylate cyclase activation was confirmed using 410.4 mammary tumor cells (Fig. 1C). In these cells, PGE₂ and PGE₁-OH induced a 1.8- and 1.6-fold increase in cAMP levels, respectively. Both responses were inhibited by RQ-15986. Thus, like AH23848, RQ-15986 effectively antagonizes EP4 in mammary tumor cells.

We then determined the effect of RQ-15986 on mammary tumor cell growth. To this aim, 66.1 cells were cultured in the presence of 0.5–10 μM RQ-15986 or vehicle and cell number was determined at 24 and 48 h. RQ-15986 did not affect the growth of tumor cells in vitro (Fig. 1D). Likewise, the proliferation of 410.4 cells was not altered in the presence of RQ-15986 (data not shown).

RQ-15986 inhibits tumor growth and metastasis in vivo. The ability of malignant cells to migrate across an artificial membrane...
in a modified Boyden chamber is a surrogate measure of metastasis. PGE₂ and PGE₁-OH induced the migration of mammary tumor cells by 2.2- and 1.9-fold, respectively (Fig. 2A). RQ-15986 was able to completely reverse PGE₂ or PGE₁-OH-induced tumor cell migration. Based on these encouraging results, we determined the ability of RQ-15986 to inhibit lung colonization by tumor cells in vivo. To this aim, 66.1 tumor cells were incubated with 3 μM RQ-15986 or vehicle for 15 min, washed and intravenously injected into syngenic BALB/cByJ female mice. Twenty-one days later, mice were euthanized and visceral metastases were enumerated. Mice injected with vehicle-treated tumor cells had an average of 49.6 ± 5 tumor colonies in the lungs, which were significantly less in mice injected with RQ-15986-treated tumor cells (Fig. 2B, 15.2 ± 5, p < 0.003). Three of ten mice injected with vehicle-treated tumor cells also had grossly detectable tumor colonies on the heart, but 0/10 mice injected with RQ-15986-treated cells displayed cardiac metastases.

NK cells play an important role in controlling tumor dissemination. Vehicle-treated mammary tumor cells injected in BALB/cByJ mice depleted of NK cells produced more lung colonies (214 ± 8) than the same cells injected in control mice (Fig. 2B), consistent with a protective role of endogenous NK cells. RQ-15986 was no longer able to limit the number of lung lesions (221.6 ± 9) in NK-depleted mice, indicating a critical role for NK cells in the mechanism by which EP4 antagonists inhibit metastasis. Sixty and 40% of NK-depleted mice displayed cardiac metastases after the injection of vehicle-treated vs. RQ-15986-treated tumor cells, respectively (data not shown).

To assess the effect of EP4 antagonism on tumor growth and spontaneous metastasis, 5 × 10⁶ 66.1 tumor cells were implanted proximal to the mammary gland of BALB/cByJ mice. Beginning on the next day, mice were treated twice a day with 100 mg/Kg RQ-15986 or vehicle for 21 d. Tumor volume was determined by caliper measurement and mice were euthanized when primary tumors achieved an average diameter of 18 mm, followed by the quantification of visceral metastases. Daily treatment with RQ-15986 resulted in an approximate 50% reduction in tumor volume (Fig. 2C, which was significantly lower starting after day 21). Spontaneous metastases to the lungs were reduced by 44% (Fig. 2D, 10.7 ± 2.5 vs. 19.2 ± 1.9, p = 0.01). Time to euthanasia (tumor > 18 mm) was also significantly extended by treatment with the EP4 antagonist (Fig. 2E, p = 0.0003).

RQ-15986 rescues NK cells from immunosuppression. We have shown that NK cells are critical for the control of tumor dissemination (Fig. 2B and ref. 8) but NK-cell functions are profoundly suppressed in advanced malignancy. We assessed the capacity of RQ-15986 to rescue NK cells from PGE₂-mediated immunosuppression. We first isolated NK-cell enriched populations from the spleens of normal BALB/cByJ mice by magnetic bead separation of DX5⁺CD3⁻ cells, and examined the ability of RQ-15986 to protect NK-cell functions (migration, cytokine production) from PGE₂-mediated inhibition. NK cells were pretreated with either vehicle or PGE₂-OH for 30 min in the absence or presence of 3 μM RQ-15986. Then, NK cells were stimulated with 1,000 U/mL interleukin-2 (IL-2) for 18 h, after which conditioned culture media were harvested and assayed for interferon γ (IFNγ) levels by ELISA. The ability of NK cells to produce IFNγ upon IL-2 stimulation was completely suppressed in the presence of PGE₂-OH (Fig. 3A). RQ-15986 was able to completely protect NK cells from the immunosuppressive effects of PGE₂-OH, restoring IFNγ production to the levels observed in control NK cells. We also determined the effect of PGE₂ on NK-cell migration. The ability of NK cells to migrate in response to fetal bovine serum (FBS) was depressed in the presence of PGE₂-OH, an inhibitory effect that was prevented by EP4 antagonism with RQ-15986 (Fig. 3B).

We then determined if RQ-15986 might protect NK cells from the functional inhibition that occurs in tumor-bearing mice. To this aim, we compared the functional activity of NK cells isolated from normal mice (N-NK cells) or 66.1 cell-derived tumor-bearing mice (T-NK cells) that either received vehicle or 100 mg/Kg RQ-15986 twice a day for 21 d. The ability of T-NK cells obtained from vehicle-treated mice to produce IFNγ was nearly absent as compared with that of N-NK cells (Fig. 4A), indicating a profound suppression of NK cells by the tumor environment. Notably, RQ-15986 was able to reverse such a tumor-associated immune dysfunction. T-NK cells from RQ-15986-treated mice indeed produced IFNγ levels that were comparable to those generated by N-NK cells. Along similar lines, T-NK cells from vehicle-treated mice migrated poorly in response to FBS as well as upon chemotactic stimulation with the chemokines macrophage inflammatory protein 1α (MIP1α) and stromal cell derived factor 1α (SDF1α), compared with N-NK cells (Fig. 4B). The administration of RQ-15986 to tumor-bearing mice rescued T-NK cells from this inhibition.

Discussion

The suppression of NK-cell functions in patients with breast cancer is partially attributable to PGE₂, which is generated in large amounts by the elevated activity of COX-2 that is common to many epithelial tumors. PGE₂ directly inhibits NK-cell functions primarily by binding EP4 receptors expressed on their surface. The results of clinical trials testing COX-2 inhibitors in cancer patients have been disappointing. The recent literature supports a potential benefit for targeting the COX-2 signaling pathway further downstream, at the level of individual EP receptors. However this branch of research has been hampered by the absence of clinically relevant EP4 antagonists. RQ-15986 is one of several high-affinity EP4 antagonists recently developed by RaQualia Pharma, Inc. The RQ-15986-related compound RQ-07 has been investigated in four Phase I studies in healthy subjects and two Phase IIa trials in patients with osteoarthritis-associated pain and found to be safe and effective (unpublished observations). RQ-15986 has been shown to inhibit primary tumorigenesis in a model of inflammatory gastric cancer, but the ability of this compound to modulate NK-cell functions and to inhibit tumor metastasis had not yet been investigated. Our findings provide support for the evaluation of the antineoplastic activity of novel EP4 antagonists in clinical trials.

Like many epithelial cancer cells, the mammary tumor cells used in this study produce significant levels of PGE₂, both in vitro and in vivo.
vivo. In our previous studies, we found cultured 66.1 cells to secrete 19.7 ± 3.4 ng/10⁶ cells PGE₂ in 48 h, while 410.4 cells released 18.2 ± 1.9 ng/10⁶ cells PGE₂. In 66.1 and 410.4-cell derived tumor homogenates, PGE₂ was quantified as 337 ± 70 and 321 ± 45 ng/g wet weight of tissue, respectively. In addition to the intrinsic

COX-2 activity of mammary tumor cells, other cells in the tumor microenvironment including fibroblasts and myeloid cells can contribute to the increased production of PGE₂. Experiments in which tumor cells were pre-treated with an EP₄ antagonist point to a direct role for EP₄ expression in the cell-intrinsic properties.
NK-cell functions are profoundly inhibited in patients with advanced malignancies and in mammary tumor-bearing mice. Here, we have shown that the treatment of these mice with RQ-15986 leads to a nearly complete rescue of NK-cell functions. This is quite interesting because other non-prostaglandin tumor products also inhibit NK cells in vitro. For example, COX-2 upregulates indoleamine-pyrrole 2,3-dioxygenase (IDO), a potent immunosuppressive mediator, implying that contribute to their metastatic potential. Our previous findings also suggest that NK-mediated tumor cell lysis is enhanced in the presence of EP4 antagonists, a phenomenon that is mechanistically linked to a reduced expression of NK-inhibitory MHC Class I molecules. Thus, EP4 antagonists inhibit tumor metastasis by multiple mechanisms, including reduced tumor cell migration, increased sensitivity to NK-mediated lysis and systemic protection of NK cells from PGE2-mediated immunosuppression.

Figure 2 (See previous page). Antineoplastic and antimetastatic effects of RQ-15986. (A) Murine 66.1 mammary tumor cells labeled with calcein AM and placed in the upper well of a Boyden chamber containing 8 μm membranes coated with collagen I and fibronectin. Five μM PGE2 or PGE1-OH, 2% FBs and/or 3 μM RQ-15986 were placed in bottom chamber, and migration was assessed at 24 h. (B) Tumor cells were cultured in the presence of 3 μM RQ-15986 for 30 min were washed and injected (1 × 10³ live cells) into the lateral tail vein of control BALB/cByJ female mice or mice depleted of NK cells with anti-asialo GM1 antibodies. All mice were euthanized on day 18–22 and soft tissues were examined for surface tumor colonies (10 mice/group). p < 0.003, vehicle-treated vs. RQ-15986-treated control mice. (C,D) Five × 10⁷ 66.1 tumor cells were subcutaneously injected proximal to the right abdominal mammary gland to BALB/cByJ female mice (day = 0, 10 mice/group). Beginning on day +1, mice were treated with 100 mg/Kg RQ-15986 twice a day by oral gavage for 21 d. Tumor diameters were monitored and mice were euthanized on an individual basis when tumors measured 18 mm in average diameter or earlier, if moribund (C), *p = 0.0004; **p < 0.0001, and surface lung tumor colonies were counted (D, p = 0.01). (E) Survival fraction plotted as number of surviving animals, i.e., not euthanized, at each time point. At the beginning of the experiment, there were 13 mice in the vehicle-treated group and 14 in the RQ-15986 treatment group (p = 0.0003).

Figure 3. Effects of RQ-15986 in NK cells. (A) Splenic NK cells isolated from normal mice as the DX5⁺CD3⁻ cell population were treated with DMSO, 5 μM PGE1-OH and/or 3 μM RQ-15986 for 30 min followed by treatment with 1000 U/mL interleukin-2 (IL-2) for 18 h. Conditioned media were then assayed for interferon γ (IFNγ) levels by ELISA, in triplicate replicates. (B) NK cells were treated with 1 μM PGE1-OH for 10 min and allowed to migrate across the top of a microplate (3 μm pore size) for 3 h in response to fetal bovine serum (FBS).
cancer and an EP4 antagonist inhibits growth in two xenograft models of castration-resistant disease. EP4 positively regulates the expression of aromatase, leading to estrogen synthesis and reduces the expression of BRCA1 in breast cancer. In addition to affecting tumor cell proliferation, EP4 plays a key role in promoting tumor cell dissemination in breast, lung and colon cancer. Both the pharmacologic antagonism of EP4 and EP4 gene silencing inhibits tumor cell invasion, migration and metastasis in preclinical models of invasive ductal carcinoma and inflammatory breast cancer. Thus, EP4 is a relevant target in multiple histologically diverse neoplasms.

Many of these studies, including our own, were performed using a commercially available EP4 antagonist, AH23848, a compound that is not compatible with clinical development. Here, we provide for the first time evidence that a novel family of compounds, developed by RaQualia Pharma may constitute effective EP4 antagonists in cancer. We employed RQ-15986 because it exhibits an excellent pharmacological profile in rodents. RQ-07, a similar compound, has been shown to be safe and efficient against osteoarthritis-associated pain in clinical trials. To our knowledge, RQ-07 is the only EP4 antagonist that is ready for evaluation as an antineoplastic agent in clinical trials.

The current study demonstrates that RQ-15986 is able to markedly inhibit breast cancer metastasis, likely due to both the protective effect of EP4 antagonism on critical NK-cell functions as well as direct effects on tumor cells. These findings add to the growing literature supporting a key role for EP4 in promoting tumor metastasis and provide a potentially novel approach to prevent cancer-associated immunosuppression. Our results support the further examination of EP4 as a new therapeutic target in multiple malignancies.

**Materials and Methods**

**Cells.** Highly tumorigenic and metastatic 66.1 and 410.4 cells were derived from a spontaneously occurring mammary adenocarcinoma in a BALB/cfC3H mouse. Cells were maintained as previously described.

**Mice.** BALB/cByJ female mice (Jackson Laboratory, 001026) were housed, cared for and used in strict accordance with the
US. Department of Agriculture regulations and the NIH Health Guide for the Care and Use of Laboratory Animals.

In vivo studies. 5 × 10^5 tumor cells were subcutaneously injected proximal to the right abdominal mammary gland of syngeneic female mice (day = 0). On day +1–21, mice were treated twice a day with vehicle or 100 mg/Kg RQ-15986 by oral gavage. Tumor diameters were measured twice weekly and mice were euthanized on an individual basis when tumors reached 18 mm in average diameter or earlier, if moribund. Tumor volumes were calculated by the formula: \( (a \times b^2) \times 0.5236 \), where \( a \) = longest diameter and \( b \) = perpendicular diameter. The lungs were weighed and surface tumor colonies were counted in a blinded fashion. Lung colonization was evaluated by intravenously injecting 1 × 10^5 viable tumor cells into the lateral tail vein of mice which were euthanized on day 18–22 post-transplantation or earlier, if moribund. For pretreatment protocols, tumors were cultured for 30 min in the presence of 3 μM RQ-15986, washed and injected into mice. To deplete NK cells, mice were injected with 20 μL rabbit anti-asialo GM1 ganglioside antibody (Wako Bioproducts, 986-10001) or control rabbit serum 1 d before and 3 d after tumor cell injection.

cAMP assays. Cells were pretreated with 1 μM indomethacin for 24 h and transferred to complete cell culture medium containing 100 μM IBMX (Sigma Chemical Co., 17018). Agonists or antagonists were added to cells and incubated for 15 min. Intracellular cAMP levels were determined using either the Amersham cAMP Biotrak EIA kit (Fig. 1B) or the cAMP EIA system (Cayman Chemicals, 581-001) (Fig. 1C). Software provided with the latter kit allowed for the conversion of binding data to pM cAMP.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank RaQualia Pharma, Inc. for the generous provision of RQ-15986 and scientific discussions. The authors received grant support from the US Department of Health and Human Services (CA120278), US Department of Veterans Affairs, US Department of Defense.

**References**

1. Holt DM, Ma X, Kundu N, Fulton AM. Prostaglandin E2 (PGE(2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother 2011; 60:1577-86; PMID:21681369; http://dx.doi.org/10.1007/s00262-011-0419-9.

2. Holt DM, Ma X, Kundu N, Collin PD, Fulton AM. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 2012; 35:179-88; PMID:22306906; http://dx.doi.org/10.1097/CJI.0b013e3182475e59.

3. Timoshenko AV, Xu G, Chakrabarty S, Lala PK, Chakrabarti S. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003; 289:265-74; PMID:14499627; http://dx.doi.org/10.1006/excr.2003.2909.

4. Robertson FM, Simeone A-M, Mazumdar A, Shah AH, McMurray JS, Ghosh S, et al. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol 2008; 7:299-312; PMID:19327010.

5. Robertson FM, Simeone A-M, Lucchi A, McMurray JS, Ghosh S, Cristofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP2 and EP4. Cancer 2010; 116(suppl):2804-14; PMID:20503412; http://dx.doi.org/10.1002/cncr.25167.

6. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66:2923-7; PMID:16540639; http://dx.doi.org/10.1158/0008-5472.CAN-05-4348.

7. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66:9794-7; PMID:17047037; http://dx.doi.org/10.1158/0008-5472.CAN-06-2067.

8. Kundu N, Ma X, Holt D, Ghoshbeha O, Ozrand-Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 2009; 117:235-42; PMID:18792778; http://dx.doi.org/10.1007/s10549-008-0180-5.

9. Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM. Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat 2012; 132:1001-8; PMID:22763157; http://dx.doi.org/10.1007/10549-011-1675-z.

10. Murase A, Tanigushi Y, Tonai-Kachi H, Nakao K, Takada J. In vitro pharmacological characterization of CJ-024794, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Life Sci 2008; 82:226-32; PMID:18155068; http://dx.doi.org/10.1016/j.lifesci.2007.11.002.

11. Mameissere E, Sylvain A, Thibault M-L, Houvenaeghel G, Jacquierm J, Castellano R, et al. Human breast cancer cells exhibit self tolerance by promoting evasion from NK cell tumor immunity. J Clin Invest 2011; 121:3609-22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816.

12. Oshima H, Hiski K, Popivanov K, Oguma K, Mani C, Rooijen N, Ishikawa T-O, et al. Prostaglandin E2 (PGE(2)) suppresses natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72:407-15; PMID:22258454; http://dx.doi.org/10.1158/0008-5472.CAN-11-2544.

13. Kundu N, Yang Q, Dorsey R, Fulton AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 2001; 95:681-6; PMID:11477578; http://dx.doi.org/10.1002/ijc.1397.

14. Balsamo M, Scardamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Nail Acad Sci U S A 2009; 106:2047-52; PMID:19394556; http://dx.doi.org/10.1073/pnas.0906481106.

15. Erusalov E, Daukin I, Ortiz J, Vieweg, J, Kusmartsev S. Pivovar Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2, carboxylase in myeloid cells. J Leukoc Biol 2010; 88:839-48; PMID:20587738; http://dx.doi.org/10.1189/jlb.1208281.

16. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Perrotto A, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72:407-15; PMID:22258454; http://dx.doi.org/10.1158/0008-5472.CAN-11-2544.

17. Basu GD, Tindler TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006; 177:2391-402; PMID:16888001.

18. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007; 7:351-40; PMID:17305476; http://dx.doi.org/10.2174/156800907780080696.

19. Reader JC, Holt D, Fulton AM. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011; 30:449-63; PMID:22020714; http://dx.doi.org/10.1007/s10555-011-9303-2.
20. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006; 66:3106-15; PMID:16540660; http://dx.doi.org/10.1158/0008-5472.CAN-05-3702.

21. Hawcroft G, Ko CWS, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007; 26:5006-19; PMID:17136837; http://dx.doi.org/10.1038/sj.onc.1210113.

22. Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, Stanlova L, Shahn NA, LaFleur BJ, et al. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther 2012; 13:175-83; PMID:22353936; http://dx.doi.org/10.4161/cbt.13.3.18874.

23. Cherukuri DP, Chen XBO, Goulet A-C, Young RN, Han Y, Heimark RL, et al. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res 2007; 313:2969-79; PMID:17631291; http://dx.doi.org/10.1016/j.yexcr.2007.06.004.

24. George RJ, Sturmoski MA, Anant S, Houchen CW. EP4 mediates PGE2-dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 2007; 83:112-20; PMID:17259077; http://dx.doi.org/10.1016/j.prostaglandins.2006.10.005.

25. Zheng Y, Rizenthaler JD, Sun X, Roman J, Han S-W. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res 2009; 69:896-904; PMID:19176380; http://dx.doi.org/10.1158/0008-5472.CAN-08-2677.

26. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008; 68:7750-9; PMID:18829259; http://dx.doi.org/10.1158/0008-5472.CAN-08-2677.

27. Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 2010; 70:1606-15; PMID:20145136; http://dx.doi.org/10.1158/0008-5472.CAN-09-2984.

28. Subbaramaiah K, Hudis C, Chang S-H, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 2008; 283:3433-44; PMID:18083712; http://dx.doi.org/10.1074/jbc.M705409200.

29. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 2006; 103:1492-7; PMID:16432186; http://dx.doi.org/10.1073/pnas.0510562103.

30. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006; 66:9665-72; PMID:18829259; http://dx.doi.org/10.1158/0008-5472.CAN-06-1271.